Table 2. Worldwide prevalence of HPV infection in different subtypes of breast cancer.
| Country | TNBC | Her2+ | Luminal B | Luminal A | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HPV (%) | HPV16/18/33 (%) | Other HPV (%) |
HPV (%) | HPV16/18/33 (%) | Other HPV (%) | HPV (%) | HPV16/18/33 (%) | Other HPV (%) | HPV (%) | HPV16/18/33 (%) | Other HPV (%) | ||||
| Algeria [Corbex et al. 2014] (50) | 5/25, 20.0 | 4/25, 16.0 | 1/25, 4.0 | – | – | – | – | – | – | – | – | – | |||
| Italy [Piana et al. 2014] (51) | 6/40, 15.0 | 28.6 | 14.3 | 0/2, 0.0 | – | – | – | – | – | 0/38, 0.0 | – | – | |||
| Australia [Lawson et al. 2015] (35) | 1/2, 50.0 | 1/2, 50.0 | – | 2/2, 100.0 | 2/2, 100.0 | – | 18/22, 81.8 | 14/22, 81.8 | 4/22, 18.1 | 3/6, 50.0 | 3/6, 50.0 | – | |||
| Spain [Vernet-Tomas et al. 2015] (52) | 0/16, 0.0 | – | – | – | – | – | – | – | – | – | |||||
| Venezuela [Fernandes et al. 2015] (53) | 2/2, 100 | – | – | 0 | – | – | 4/7, 54.1 | – | – | 4/13, 30.7 | – | – | |||
| India [Islam et al. 2017] (38) | 37/67, 55.2 | – | – | 56/84, 66.6 | – | – | 58/83, 69.9 | – | – | 23/38, 60.5 | – | – | |||
| Spain [Delgado-García et al. 2017] (39) | 11/24, 8.7 | – | – | 5/12, 4.0 | – | – | 73/118, 61.8 | – | – | 37/88, 29.4 | – | – | |||
| Morocco [Habyarimana et al. 2018] (54) | 4\9, 44.4 | 2\2, 100.0 | 2\2, 100.0 | 3\6, 50.0 | 2\3, 66.6 | 1\3, 33.3 | 3\10, 30.0 | 2\3, 66.6 | 1\3, 33.3 | 12\21, 57.1 | 11\12, 91.6 | 1\12, 8.3 | |||
TNBC, triple negative breast cancer.